In another study performed by van Engen-van Grunsven et al., they evaluated a series of primary melanomas of the female urogenital tract for oncogenic mutations in KIT, NRAS, and BRAF in order to identify patients who may be amenable to targeted therapy. This evidence concerns the gene BRAF and melanoma.